Tags

Type your tag names separated by a space and hit enter

Present and future therapeutic strategies for melioidosis and glanders.
Expert Rev Anti Infect Ther. 2010 Mar; 8(3):325-38.ER

Abstract

Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases.

Authors+Show Affiliations

Department of Microbiology and Immunology, Department of Pathology and The Sealy Center for Vaccine Development, University of Texas Medical Branch, Galveston, TX 77555-1070, USA. dmestes@utmb.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

20192686

Citation

Estes, D Mark, et al. "Present and Future Therapeutic Strategies for Melioidosis and Glanders." Expert Review of Anti-infective Therapy, vol. 8, no. 3, 2010, pp. 325-38.
Estes DM, Dow SW, Schweizer HP, et al. Present and future therapeutic strategies for melioidosis and glanders. Expert Rev Anti Infect Ther. 2010;8(3):325-38.
Estes, D. M., Dow, S. W., Schweizer, H. P., & Torres, A. G. (2010). Present and future therapeutic strategies for melioidosis and glanders. Expert Review of Anti-infective Therapy, 8(3), 325-38. https://doi.org/10.1586/eri.10.4
Estes DM, et al. Present and Future Therapeutic Strategies for Melioidosis and Glanders. Expert Rev Anti Infect Ther. 2010;8(3):325-38. PubMed PMID: 20192686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Present and future therapeutic strategies for melioidosis and glanders. AU - Estes,D Mark, AU - Dow,Steven W, AU - Schweizer,Herbert P, AU - Torres,Alfredo G, PY - 2010/3/3/entrez PY - 2010/3/3/pubmed PY - 2010/6/2/medline SP - 325 EP - 38 JF - Expert review of anti-infective therapy JO - Expert Rev Anti Infect Ther VL - 8 IS - 3 N2 - Burkholderia pseudomallei and Burkholderia mallei are the causative agents of melioidosis and glanders, respectively. Both Gram-negative pathogens are endemic in many parts of the world. Although natural acquisition of these pathogens is rare in the majority of countries, these bacteria have recently gained much interest because of their potential as bioterrorism agents. In modern times, their potential destructive impact on public health has escalated owing to the ability of these pathogens to cause opportunistic infections in diabetic and perhaps otherwise immunocompromised people, two growing populations worldwide. For both pathogens, severe infection in humans carries a high mortality rate, both species are recalcitrant to antibiotic therapy - B. pseudomallei more so than B. mallei - and no licensed vaccine exists for either prophylactic or therapeutic use. The potential malicious use of these organisms has accelerated the investigation of new ways to prevent and to treat the diseases. The availability of several B. pseudomallei and B. mallei genome sequences has greatly facilitated target identification and development of new therapeutics. This review provides a compilation of literature covering studies in antimelioidosis and antiglanders antimicrobial drug discovery, with a particular focus on potential novel therapeutic approaches to combat these diseases. SN - 1744-8336 UR - https://www.unboundmedicine.com/medline/citation/20192686/Present_and_future_therapeutic_strategies_for_melioidosis_and_glanders_ L2 - https://www.tandfonline.com/doi/full/10.1586/eri.10.4 DB - PRIME DP - Unbound Medicine ER -